神经科指南

订阅

MedSci主页 / 所有栏目 / 神经科指南

2021 MSIF指南：多发性硬化的超说明书治疗

2021-12-07 多发性硬化国际联合会 Mult Scler J Exp Transl Clin

多发性硬化症中枢神经脱髓鞘疾病

2021年12月，多发性硬化国际联合会(MSIF)发布了多发性硬化的超说明书治疗指南。

中文标题：

2021 MSIF指南：多发性硬化的超说明书治疗

英文标题：

Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis

发布机构：

多发性硬化国际联合会

发布日期：

2021-12-07

简要介绍：

2021年12月，多发性硬化国际联合会(MSIF)发布了多发性硬化的超说明书治疗指南。全球范围内约有280万多发性硬化（MS）确诊患者，其中25%居住在中低收入国家。对于MS患者，疾病修饰疗法的可用性存在差异。本文主要针对MS的超说明书用药提供指导。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 MSIF指南：多发性硬化的超说明书治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a6c201c002291eea, title=2021 MSIF指南：多发性硬化的超说明书治疗, enTitle=Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis, guiderFrom=Mult Scler J Exp Transl Clin, authorId=0, author=, summary=2021年12月，多发性硬化国际联合会(MSIF)发布了多发性硬化的超说明书治疗指南。, cover=https://img.medsci.cn/20211216/1639661427731_1608702.jpg, journalId=0, articlesId=null, associationId=2225, associationName=多发性硬化国际联合会, associationIntro=多发性硬化国际联合会(MSIF,Multiple Sclerosis International Federation), copyright=0, guiderPublishedTime=Tue Dec 07 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年12月，多发性硬化国际联合会(MSIF)发布了多发性硬化的超说明书治疗指南。全球范围内约有280万多发性硬化（MS）确诊患者，其中25%居住在中低收入国家。对于MS患者，疾病修饰疗法的可用性存在差异。本文主要针对MS的超说明书用药提供指导。</span></p>, tagList=[TagDto(tagId=972, tagName=多发性硬化症), TagDto(tagId=118273, tagName=中枢神经脱髓鞘疾病)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=972, guiderKeyword=多发性硬化症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2429, appHits=76, showAppHits=0, pcHits=496, showPcHits=2353, likes=0, shares=6, comments=3, approvalStatus=1, publishedTime=Thu Dec 16 21:23:05 CST 2021, publishedTimeString=2021-12-07, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Thu Dec 16 21:30:41 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Thu Jan 04 11:06:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 MSIF指南：多发性硬化的超说明书治疗.pdf)])
2021 MSIF指南：多发性硬化的超说明书治疗.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1081427, encodeId=3f32108142e34, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Dec 18 06:54:25 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080996, encodeId=31eb108099603, content=来了来了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 17 06:58:10 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080995, encodeId=e777108099558, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 17 06:57:57 CST 2021, time=2021-12-17, status=1, ipAttribution=)]
    2021-12-18 微探

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1081427, encodeId=3f32108142e34, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Dec 18 06:54:25 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080996, encodeId=31eb108099603, content=来了来了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 17 06:58:10 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080995, encodeId=e777108099558, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 17 06:57:57 CST 2021, time=2021-12-17, status=1, ipAttribution=)]
    2021-12-17 微探

    来了来了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1081427, encodeId=3f32108142e34, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Dec 18 06:54:25 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080996, encodeId=31eb108099603, content=来了来了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 17 06:58:10 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080995, encodeId=e777108099558, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Fri Dec 17 06:57:57 CST 2021, time=2021-12-17, status=1, ipAttribution=)]
    2021-12-17 微探

    学习学习

    0

相关指南

多发性硬化症及相关疾病治疗争议：2021年DGN多发性硬化症、视神经脊髓炎谱系疾病和MOG-IgG相关疾病诊断和治疗指南专家组立场声明

德国神经学会 ( Deutsche Gesellschaft für Neurologie , DGN) · 2021-08-06

2021 MSTCG立场声明：多发性硬化的疾病修饰疗法

多发性硬化治疗共识小组(MSTCG,Multiple Sclerosis Therapy Consensus Group) · 2021-08-18

多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答

多发性硬化症治疗共识小组 (MSTCG) · 2021-08-02

对符合免疫抑制治疗条件的多发性硬化症患者的疫苗接种建议：西班牙共识声明

暂未更新 · 2020-06-23

多发性硬化症患者的疾病调节药物和计划生育：海湾地区的共识

暂未更新 · 2020-06-23

2016 CMSC修订建议：标准化MRI协议和多发性硬化的诊断与随访

国际多发性硬化专家组(International Panel of MS) · 2016-03-01

拓展阅读

2016 CMSC修订建议：标准化MRI协议和多发性硬化的诊断与随访

国际多发性硬化专家组(International Panel of MS) · 2016-03-01

多发性硬化症患者的疾病调节药物和计划生育：海湾地区的共识

暂未更新 · 2020-06-23

对符合免疫抑制治疗条件的多发性硬化症患者的疫苗接种建议：西班牙共识声明

暂未更新 · 2020-06-23

多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答

多发性硬化症治疗共识小组 (MSTCG) · 2021-08-02

2021 MSTCG立场声明：多发性硬化的疾病修饰疗法

多发性硬化治疗共识小组(MSTCG,Multiple Sclerosis Therapy Consensus Group) · 2021-08-18

多发性硬化症及相关疾病治疗争议：2021年DGN多发性硬化症、视神经脊髓炎谱系疾病和MOG-IgG相关疾病诊断和治疗指南专家组立场声明

德国神经学会 ( Deutsche Gesellschaft für Neurologie , DGN) · 2021-08-06